Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MASP2 | O00187 | 1/20 | 0.47 |
| ▸ | KLKB1 | P03952 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ACACB | O00763 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3139642 | 0.89 | MASP2 (0.48) | MASP2POLB | |
| SCHEMBL3154000 | 0.85 | MASP2 (0.50) | MASP2MEN1KMT2ACPB2 | |
| SCHEMBL3153731 | 0.84 | MASP2 (0.48) | MASP2 | |
| SCHEMBL3154431 | 0.84 | MASP2 (0.56) | MASP2CPB2 | |
| SCHEMBL1903909 | 0.83 | NAMPT (0.54) | MASP2CPB2 | |
| SCHEMBL3139300 | 0.83 | MASP2 (0.47) | MASP2MEN1KMT2ACPB2 | |
| SCHEMBL3154975 | 0.83 | MASP2 (0.47) | MASP2CPB2LMNAMAPK1 | |
| SCHEMBL1903911 | 0.83 | NAMPT (0.54) | MASP2CPB2 | |
| SCHEMBL4309246 | 0.83 | MEN1 (0.43) | MASP2KLKB1POLBMEN1KMT2A | |
| SCHEMBL3139988 | 0.82 | MASP2 (0.48) | MASP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | VANTIA LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | CHRM1, ARG1, ARG2 | MASP2 3039/4885KLKB1 3491/4885POLB 1602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.